These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30638863)

  • 21. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
    Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
    Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.
    Dawood FS; Jara J; Gonzalez R; Castillo JM; De León T; Estripeaut D; Luciani K; Sujey Brizuela Y; Barahona A; Cazares RA; Lawson AM; Rodriguez M; de Viana D; Franco D; Castillo M; Fry AM; Gubareva L; Tamura D; Hughes M; Gargiullo P; Clara W; Azziz-Baumgartner E; Widdowson MA
    Antiviral Res; 2016 Sep; 133():85-94. PubMed ID: 27451343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.
    Pleguezuelos O; Robinson S; Fernández A; Stoloff GA; Mann A; Gilbert A; Balaratnam G; Wilkinson T; Lambkin-Williams R; Oxford J; Caparrós-Wanderley W
    Clin Vaccine Immunol; 2015 Jul; 22(7):828-35. PubMed ID: 25994549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.
    Ramos EL; Mitcham JL; Koller TD; Bonavia A; Usner DW; Balaratnam G; Fredlund P; Swiderek KM
    J Infect Dis; 2015 Apr; 211(7):1038-44. PubMed ID: 25281755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.
    Lim JJ; Nilsson AC; Silverman M; Assy N; Kulkarni P; McBride JM; Deng R; Li C; Yang X; Nguyen A; Horn P; Maia M; Castro A; Peck MC; Galanter J; Chu T; Newton EM; Tavel JA
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32393496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial.
    Hung IFN; To KKW; Chan JFW; Cheng VCC; Liu KSH; Tam A; Chan TC; Zhang AJ; Li P; Wong TL; Zhang R; Cheung MKS; Leung W; Lau JYN; Fok M; Chen H; Chan KH; Yuen KY
    Chest; 2017 May; 151(5):1069-1080. PubMed ID: 27884765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model.
    Han A; Poon JL; Powers JH; Leidy NK; Yu R; Memoli MJ
    BMC Infect Dis; 2018 Jul; 18(1):353. PubMed ID: 30055573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
    Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.
    Baranovich T; Jones JC; Russier M; Vogel P; Szretter KJ; Sloan SE; Seiler P; Trevejo JM; Webby RJ; Govorkova EA
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2118-31. PubMed ID: 26787699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR].
    Kiselev OI; Maleev VV; Deeva EG; Leneva IA; Selkova EP; Osipova EA; Obukhov AA; Nadorov SA; Kulikova EV
    Ter Arkh; 2015; 87(1):88-96. PubMed ID: 25823275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
    Wang C; Cao B; Liu QQ; Zou ZQ; Liang ZA; Gu L; Dong JP; Liang LR; Li XW; Hu K; He XS; Sun YH; An Y; Yang T; Cao ZX; Guo YM; Wen XM; Wang YG; Liu YL; Jiang LD
    Ann Intern Med; 2011 Aug; 155(4):217-25. PubMed ID: 21844547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.
    Nicholson KG; Aoki FY; Osterhaus AD; Trottier S; Carewicz O; Mercier CH; Rode A; Kinnersley N; Ward P
    Lancet; 2000 May; 355(9218):1845-50. PubMed ID: 10866439
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Sutton TC; Lamirande EW; Bock KW; Moore IN; Koudstaal W; Rehman M; Weverling GJ; Goudsmit J; Subbarao K
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29046448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
    Lim JJ; Derby MA; Zhang Y; Deng R; Larouche R; Anderson M; Maia M; Carrier S; Pelletier I; Girard J; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection.
    Lim JJ; Dar S; Venter D; Horcajada JP; Kulkarni P; Nguyen A; McBride JM; Deng R; Galanter J; Chu T; Newton EM; Tavel JA; Peck MC
    Open Forum Infect Dis; 2022 Feb; 9(2):ofab630. PubMed ID: 35106315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A broadly neutralizing human monoclonal antibody is effective against H7N9.
    Tharakaraman K; Subramanian V; Viswanathan K; Sloan S; Yen HL; Barnard DL; Leung YH; Szretter KJ; Koch TJ; Delaney JC; Babcock GJ; Wogan GN; Sasisekharan R; Shriver Z
    Proc Natl Acad Sci U S A; 2015 Sep; 112(35):10890-5. PubMed ID: 26283346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized controlled trial of the effect of regular paracetamol on influenza infection.
    Jefferies S; Braithwaite I; Walker S; Weatherall M; Jennings L; Luck M; Barrett K; Siebers R; Blackmore T; Beasley R; Perrin K;
    Respirology; 2016 Feb; 21(2):370-7. PubMed ID: 26638130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.